Welcome to our dedicated page for Si-Bone SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SI-BONE, Inc. filings document formal disclosures for a Nasdaq-listed medical device company developing surgical technologies for compromised bone and sacropelvic disorders. Recent Form 8-K reports furnish quarterly results, preliminary revenue and cash information, Regulation FD presentation materials, and material agreements such as facility lease arrangements.
The company’s proxy materials cover annual meeting matters, board composition, executive compensation, equity awards, and pay-versus-performance disclosure. Additional 8-K disclosures record governance and leadership changes, including board resignations, committee updates, officer transitions, and related compensatory arrangements.
SI-BONE, Inc. (SIBN) – Form 4 filing dated 07/07/2025
Senior Vice President, Operations & Administration and Chief Legal Officer Michael A. Pisetsky reported a routine “sell-to-cover” transaction tied to the vesting of restricted stock units (RSUs) on 07/02/2025. To satisfy withholding taxes, Pisetsky sold an aggregate 3,127 common shares in three market transactions at weighted-average prices between $18.26 – $18.38 per share.
Following the sales, the executive retains 261,681 common shares, which includes 145,043 shares underlying un-settled RSUs. No derivative securities were involved, and the filing states the sales were non-discretionary and solely for tax purposes.
The disposition represents approximately 1.2 % of the executive’s post-transaction holdings and does not alter overall insider ownership meaningfully. There is no indication of strategic intent or change in outlook for SIBN; the filing is considered administratively routine under Section 16 rules.